Oxaceprol
| Evidence Level: L5 | Predicted Indications: 9 |
Table of Contents
Oxaceprol: From Osteoarthritis to Ankylosing Spondylitis
One-Sentence Summary
Oxaceprol is a proline derivative (N-acetyl-hydroxyproline) used for joint conditions such as osteoarthritis. The TxGNN model predicts it may be effective for ankylosing spondylitis, but no clinical trials and no publications were found to support this prediction, so it rests on model output alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Osteoarthritis and arthropathy (relations recorded in the knowledge graph; the licence records compiled for this report contain no indication text) |
| Predicted New Indication | Ankylosing spondylitis |
| TxGNN Prediction Score | 0.9995 |
| Evidence Level | L5 |
| India Market Status | Listed in a compiled Indian medicine price dataset (at least 20) – CDSCO approval status is not included in this data |
| Number of Listed Products | at least 20 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available. Oxaceprol is generally described as a proline derivative with a proposed effect on cartilage metabolism and reduced leukocyte infiltration into joints. These points come from general knowledge rather than from the data compiled for this report, and they should be verified.
The score for ankylosing spondylitis (0.9995) comes from the TxGNN model (deep learning) and may reflect similarities the model learned between related diseases, not biological evidence.
However, ankylosing spondylitis is an axial, HLA-B27-associated spondyloarthritis driven mainly by IL-17 and TNF pathways. Its biology differs substantially from degenerative joint disease, so the mechanistic connection is weak. The high score (0.9995) is a model prediction only and has not been validated.
Other top predictions are mostly rare skeletal dysplasias or autoimmune arthritis variants (for example juvenile idiopathic arthritis, rheumatoid vasculitis and pseudoachondroplasia). None has any supporting trial or publication in the compiled data.
India Market Information
Oxaceprol is marketed in India. At least 20 single-ingredient registrations are on record, and the list may be partial. No approved indication text is recorded in these licences.
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 171698 | Oxasoft 200mg Capsule | Strip of 10 capsules | Not recorded |
| 116504 | Kneerol OD Tablet SR | Strip of 10 SR tablets | Not recorded |
| 215745 | Trueceprol OD Tablet SR | Strip of 10 SR tablets | Not recorded |
| 79019 | Ezrol Capsule | Strip of 10 capsules | Not recorded |
| 40609 | Ceprol Tablet SR | Strip of 10 SR tablets | Not recorded |
All listed products are oral forms (capsules, tablets, sustained-release and extended-release tablets).
Safety Considerations
Please refer to the package insert for safety information. No warnings or contraindications were available in the data compiled for this report, and no drug interaction records were found.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction has no supporting clinical trials or publications for ankylosing spondylitis, and the mechanistic link is weak. The evidence level is L5 (model prediction only).
To proceed, the following is needed:
- Mechanism of action data for oxaceprol, to test relevance to IL-17/TNF-driven axial inflammation
- Package insert warnings, contraindications and indication text from Indian licences
- Preclinical or early clinical evidence directly studying oxaceprol in ankylosing spondylitis
- A review of whether other candidates, such as rheumatoid or juvenile arthritis variants, have better supporting evidence
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.